Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab
Authors:
- Giulia MaddalenaGMGiulia Maddalena
- Ymke van der PolYPYmke van der Pol
- Oscar E VillarrealOVOscar E Villarreal
- Oluwadara CokerOCOluwadara Coker
- Hey Min LeeHLHey Min Lee
- Zach RiversZRZach Rivers
- Wendy CovertWCWendy Covert
- Stacy DiaoSDStacy Diao
- Sara LonardiSLSara Lonardi
- Jane E RogersJRJane E Rogers
- Arvind DasariADArvind Dasari
- Justin GuinneyJGJustin Guinney
- 30 December 2025
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (5) , 903-908
Abstract
Background: Clinical benefit from later lines of therapy in metastatic colorectal cancer (mCRC) is limited. Patient selection for treatment is crucial for optimal risk-benefit evaluation. Codon-specific KRAS mutations have been implicated as predictive biomarkers for efficacy of trifluridine/tipiracil (TAS-102). However, their predictive impact for TAS-102 plus Bevacizumab (TAS-Bev), the new standard of care in mCRC, is unknown. Methods: This large patient-based, real-world, retrospective cohort study of mCRC patients who received TAS-102 alone or in combination with bevacizumab between January 1, 2020, and March 1, 2023. A sensitivity analysis was performed in 2 independent cohorts from MD Anderson Cancer Center, Houston, TX, and Tempus AI, Inc., Chicago, IL, prior to polling the data together. Results: A total of 946 mCRC patients were evaluated; KRAS was mutated in 57.8% cases, 39.4% involving G12 codon, and 9.8% G13. We found no association of KRAS-G12 mutations with overall survival (hazard ratio [HR] = 1.1, 95% confidence interval [CI] = 0.90 to 1.25; P = .441) on TAS-102 contradicting the reported predictive impact of these biomarkers. Moreover, we reported inferior overall survival for KRAS-G13 mutant patients (HR = 1.3, 95% CI = 1.02 to 1.69; P = .045). On TAS-Bev, no association was found between KRAS-G12 (HR = 0.8, 95% CI = 0.59 to 1.11; P = .188) or KRAS-G13 (HR = 1.66, 95% CI = 0.99 to 2.79; P = .072) mutations and overall survival. Conclusions: No significant associations between KRAS-G12 and overall survival were found for TAS-102 or TAS-Bev. Further research is needed to assess the impact of these mutations on combined TAS-Bev therapy prior to any clinical application.Keywords
Funding Information
- CPRIT Research Training (RP210028)
This publication has 7 references indexed in Scilit:
- Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trialESMO Open, 2024
- Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancerESMO Open, 2023
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyThe Lancet, 2023
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2023
- Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerNature Medicine, 2023
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013